Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Significance: Currently there are no targeted therapies for KRAS mutant cancer. Our study uncovers a critical role of the small ubiquitin-like modifier (SUMO) E2 ligase Ubc9 in sustaining the transformation growth of KRAS mutant colorectal cancer cells, thus establishing a functional link between the SUMO pathway and the KRAS oncogene. SUMO ligases are poorly explored drug targets; our work suggests that targeting the SUMO pathway, and Ubc9 in particular, could be potentially useful for the treatment of KRAS mutant colorectal cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“KRAS mutations occur in ∼60% of pancreatic ductal carcinomas, 26% of lung adenocarcinomas, and 45% of colorectal carcinomas, as well as a significant fraction of ovarian, endometrial, and biliary track cancers (2, 3).”
Anoikis molecular pathways and its role in cancer progression
Paoli, P., Giannoni, E., & Chiarugi, P. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.06.026 · Cited by 1,160 · cited 1×
“Clonogenic growth, particularly under AI conditions, is inhibited in normal cells as they undergo anoikis upon loss of attachment (34).”
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 4×
“The SUMO E1 ligase gene SAE1 and the E2 ligase gene UBE2I/Ubc9 scored as candidate KRAS synthetic lethal partners in our genomewide shRNA screen (7).”
MethodInfluentialSelf-citationMutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 2×
“methylation was set as a static modification and Oxidation, SILAC (13)C(6) (15)N (4) (R), and SILAC (13)C(6) were selected as variable modifications.”
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Regulation of DNA Damage Responses by Ubiquitin and SUMO
Jackson, S. P., & Durocher, D. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.017 · Cited by 601
Ivanov, A. V., Peng, H., Yurchenko, V., Yap, K. L., Negorev, D. G., Schultz, D. C., Psulkowski, E., Fredericks, W. J., White, D. E., Maul, G. G., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.012 · Cited by 432
Li, X., Lee, Y.-K., Jeng, J.-C., Yen, Y., Schultz, D. C., Shih, H.-M., & Ann, D. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706912200 · Cited by 168
Self-citation
Cited by
SUMO and the robustness of cancer
Seeler, J.-S., & Dejean, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.143 · Cited by 429
Signalling mechanisms and cellular functions of SUMO
Vertegaal, A. C. O. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00500-y · Cited by 376
Chang, H.-M., & Yeh, E. T. H. (2020) · Physiological Reviews · doi:10.1152/physrev.00025.2019 · Cited by 355
Li, Y.-J., Du, L., Wang, J., Vega, R., Lee, T. D., Miao, Y., Aldana-Masangkay, G., Samuels, E. R., Li, B., Ouyang, S. X., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.026 · Cited by 50
“For example, multiple studies indicate that SUMOylation is dysregulated in many types of cancers and that the SUMO activating enzyme (SAE, SUMO E1) could be a potential target to inhibit c-Myc and KRas-dependent oncogenesis (He et al., 2017; Kessler et al., 2011; Luo et al., 2009; Yu et al., 2015) and reduce cancer ce…”
K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion
Choi, B. H., Philips, M. R., Chen, Y., Lu, L., & Dai, W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003723 · Cited by 42
Metadata
- Authors
- Yu, B., Swatkoski, S., Holly, A., Lee, L. C., Giroux, V., Lee, C.-S., Hsu, D., Smith, J. L., Yuen, G., Yue, J., Ann, D. K., Simpson, R. M., Creighton, C. J., Figg, W. D., Gucek, M., & Luo, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-03-24
- Volume
- 112
- Issue
- 14
- Pages
- E1724-33
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2065507038
- Cited by
- 76
- References
- 11
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.